Short answer
Aquestive Therapeutics, Inc. (AQST) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $8M (down 41.0% year over year) with net income of −$16M.
Q3 2026 key financials · XBRL
- Revenue
- $8M
- −41.0% YoY · −45.3% QoQ
- Net income
- −$16M
- −6.8% YoY · +27.9% QoQ
- Operating margin
- -191.5%
- EPS (diluted)
- −$0.13
- +7.1% YoY · +27.8% QoQ
Source: XBRL data from the Aquestive Therapeutics, Inc. (AQST) Q3 2026 10-Q on SEC EDGAR. USD.
Aquestive Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $7,557, down 41% YoY from $12,807, driven by Suboxone revenue decline of approximately $5,600
- Manufacture and supply revenue $6,659, down 42% YoY, with Ondif revenue up approximately $1,100
- Operating margin not disclosed; R&D expense $4,251, down 6%, and SG&A $14,169, down 7%
- Cash $90,349 at September 30; operating cash use $31,293 versus $43,963 YoY
- Anaphylm resubmission accepted as Class 2; FDA PDUFA goal March 16, 2027, launch readiness targeted for Q1 2027 if approved
Risk Factors
- No material changes disclosed from the 2025 Form 10-K and subsequent 10-Q filings
- Carried-forward business risk: adverse effects on prospects, financial condition, results, liquidity, and available capital resources
- Risk disclosure incorporates prior filings without identifying a new trigger or updated regulatory, operational, competitive, or financial detail
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aquestive Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.